Saturday, July 11, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “Jenrin Discovery, LLC”

26 pharma patents match "Jenrin Discovery, LLC" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 26
Index total 30,257
Page 1 / 2

Quick answer

This filtered view shows 26 pharmaceutical patents matching "Jenrin Discovery, LLC" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

26 results for “Jenrin Discovery, LLC” · 30,257 patents in full index Clear search

  1. US 11179370

    Cannabinoid receptor antagonists/inverse agonists useful for treating disease conditions, including metabolic disorders and cancers

    Jenrin Discovery, LLC · Granted Nov 23, 2021 · Expires Nov 18, 2041

    granted

  2. US 10617673

    Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes

    Jenrin Discovery, LLC · Granted Apr 14, 2020 · Expires Apr 9, 2040

    granted

  3. US 9987253

    Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes

    Jenrin Discovery, LLC · Granted Jun 5, 2018 · Expires May 31, 2038

    granted

  4. US 9517228

    Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes

    Jenrin Discovery, LLC · Granted Dec 13, 2016 · Expires Dec 8, 2036

    granted

  5. US 9133127

    Cannabinoid receptor antagonists/inverse agonists useful for treating disease conditions, including metabolic disorders and cancers

    Jenrin Discovery, LLC · Granted Sep 15, 2015 · Expires Sep 10, 2035

    granted

  6. US 8853252

    Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes

    Jenrin Discovery, LLC · Granted Oct 7, 2014 · Expires Oct 2, 2034

    granted

  7. US 8716265

    4-quinolinemethanols as anti-malarial agents

    Jenrin Discovery, LLC · Granted May 6, 2014 · Expires May 1, 2034

    granted

  8. US 8680131

    Cannabinoid receptor antagonists/inverse agonists useful for treating disease conditions, including metabolic disorders and cancers

    Jenrin Discovery, LLC · Granted Mar 25, 2014 · Expires Mar 20, 2034

    granted

  9. US 8648072

    Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes

    Jenrin Discovery, LLC · Granted Feb 11, 2014 · Expires Feb 6, 2034

    granted

  10. US 8580768

    Cannabinoid receptor antagonists-inverse agonists useful for treating metabolic disorders, including obesity and diabetes

    Jenrin Discovery, LLC · Granted Nov 12, 2013 · Expires Nov 7, 2033

    granted

  11. US 8541475

    MAO-B inhibitors useful for treating obesity

    Jenrin Discovery, LLC · Granted Sep 24, 2013 · Expires Sep 19, 2033

    granted

  12. US 8334282

    Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes

    Jenrin Discovery, LLC · Granted Dec 18, 2012 · Expires Dec 13, 2032

    granted

  13. US 8252791

    Purine compounds as cannabinoid receptor blockers

    Jenrin Discovery, LLC · Granted Aug 28, 2012 · Expires Aug 23, 2032

    granted

  14. US 8236821

    Substituted N-phenyl-5-phenyl-pyrazolin-3-yl amides as cannabinoid receptor antagonists/inverse agonists useful for treating obesity

    Jenrin Discovery, LLC · Granted Aug 7, 2012 · Expires Aug 2, 2032

    granted

  15. US 8217038

    Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes

    Jenrin Discovery, LLC · Granted Jul 10, 2012 · Expires Jul 5, 2032

    granted

  16. US 8138216

    Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes

    Jenrin Discovery, LLC · Granted Mar 20, 2012 · Expires Mar 15, 2032

    granted

  17. US 8133904

    Cannabinoid receptor antagonists/inverse agonists useful for treating obesity

    Jenrin Discovery, LLC · Granted Mar 13, 2012 · Expires Mar 8, 2032

    granted

  18. US 8124802

    MAO inhibiting N-benzyl-N-propargyl-amines useful for treating obesity

    Jenrin Discovery, LLC · Granted Feb 28, 2012 · Expires Feb 23, 2032

    granted

  19. US 8088926

    Substituted 2-methyl-2-phenoxy-N-propyl-propionamides as cannabinoid receptor antagonists/inverse agonists useful for treating obesity

    Jenrin Discovery, LLC · Granted Jan 3, 2012 · Expires Dec 29, 2031

    granted

  20. US 8088809

    Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes

    Jenrin Discovery, LLC · Granted Jan 3, 2012 · Expires Dec 29, 2031

    granted

  21. US 7956220

    MAO-B inhibitors useful for treating obesity

    Jenrin Discovery, LLC · Granted Jun 7, 2011 · Expires Jun 2, 2031

    granted

  22. US 7687481

    Cannabinoid receptor antagonists/inverse agonists useful for treating obesity

    Jenrin Discovery, LLC · Granted Mar 30, 2010 · Expires Mar 25, 2030

    granted

  23. US 7666889

    Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes

    Jenrin Discovery, LLC · Granted Feb 23, 2010 · Expires Feb 18, 2030

    granted

  24. US 7655685

    Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes

    Jenrin Discovery, LLC · Granted Feb 2, 2010 · Expires Jan 28, 2030

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.